HCPCS Level II
Outpatient PPS (prospective payment system), temporary
Letter C, 622 codes. CMS HCPCS Level II file dated September 23, 2026.
License: a US government work, in the public domain (Public Domain Mark 1.0).
Run it in Rivvi
Check every code on your export
Upload a claims or charge export. Rivvi flags HCPCS codes that are deleted or replaced, with the replacement and its date.
Check my exportFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Blocks
Each block is one hundred codes. Open one instead of paging the whole letter.
Codes
361 to 400 of 622
- C9078Injection, trilaciclib, 1 mgDeleted 2021
- C9079Injection, evinacumab-dgnb, 5 mgDeleted 2021
- C9080Injection, melphalan flufenamide hydrochloride, 1 mgDeleted 2021
- C9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseDeleted 2021
- C9082Injection, dostarlimab-gxly, 100 mgDeleted 2021
- C9083Injection, amivantamab-vmjw, 10 mgDeleted 2021
- C9084Injection, loncastuximab tesirine-lpyl, 0.1 mgDeleted 2022
- C9085Injection, avalglucosidase alfa-ngpt, 4 mgDeleted 2022
- C9086Injection, anifrolumab-fnia, 1 mgDeleted 2022
- C9087Injection, cyclophosphamide, (auromedics), 10 mgDeleted 2022
- C9088Instillation, bupivacaine and meloxicam, 1 mg/0.03 mgDeleted 2025
- C9089Bupivacaine, collagen-matrix implant, 1 mgDeleted 2025
- C9090Injection, plasminogen, human-tvmh, 1 mgDeleted 2022
- C9091Injection, sirolimus protein-bound particles, 1 mgDeleted 2022
- C9092Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mgDeleted 2022
- C9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mgDeleted 2022
- C9094Inj, sutimlimab-jome, 10 mgDeleted 2022
- C9095Inj, tebentafusp-tebn, 1 mcgDeleted 2022
- C9096Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramDeleted 2022
- C9097Inj, faricimab-svoa, 0.1 mgDeleted 2022
- C9098Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic doseDeleted 2022
- C9101Injection, oliceridine, 0.1 mg
- C9113Injection, pantoprazole sodium, per vialDeleted 2024
- C9121Injection, argatroban, per 5 mgDeleted 2016
- C9122Mometasone furoate sinus implant, 10 micrograms (sinuva)Deleted 2021
- C9132Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activityDeleted 2021
- C9133Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.Deleted 2014
- C9134Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.Deleted 2014
- C9135Factor ix (antihemophilic factor, recombinant), alprolix, per i.u.Deleted 2014
- C9136Injection, factor viii, fc fusion protein, (recombinant), per i.u.Deleted 2015
- C9137Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.Deleted 2016
- C9138Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.Deleted 2016
- C9139Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.Deleted 2016
- C9140Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.Deleted 2017
- C9141Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.Deleted 2019
- C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgDeleted 2022
- C9143Cocaine hydrochloride nasal solution (numbrino), 1 mg
- C9144Injection, bupivacaine (posimir), 1 mg
- C9145Injection, aprepitant, (aponvie), 1 mgDeleted 2026
- C9146Injection, mirvetuximab soravtansine-gynx, 1 mgDeleted 2023